Prelude Capital Management’s Tourmaline Bio TRML Stock Holding History

Prelude Capital Management’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-27,282	Closed	-$1.3M	–	1554
2025 Q3	$1.3M	Buy	+27,282	New	+$757K	0.1%	249
2023 Q3	–	Sell	-1,573	Closed	-$47.8K	–	1346
2023 Q2	$47.8K	Buy	+1,573	New	+$40.2K	﹤0.01%	975

Prelude Capital Management's TRML Position: Q4 2025 in Review

Prelude Capital Management sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 27,282 shares — an estimated $1.3M sold.

Prelude Capital Management first reported a position in TRML in Q2 2023 and held it in 2 quarters. The position peaked at $1.3M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Prelude Capital Management reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Prelude Capital Management sold 27,282 Tourmaline Bio shares in Q4 2025, an estimated $1.3M.
Prelude Capital Management first reported a position in Tourmaline Bio in Q2 2023 and held it in 2 quarters.
Prelude Capital Management's Tourmaline Bio position peaked at $1.3M in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.